Pharmacological characterization of protein phosphatase activities in preparations from failing human hearts

Joachim Neumann, Renke Maas, Peter Bokník, Larry Jones, Norbert Zimmermann, Hasso Scholz

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

β-Adrenoceptor stimulation acts in the heart in part by increasing the phosphorylation state of phospholamban and phospholemman. There is evidence that the β-adrenoceptor-mediated increase in phospholamban phosphorylation is in part due to inhibition of type 1 phosphatases. The aim of the present study was to elucidate which phosphatases dephosphorylate phospholamban and phospholemman in the human heart. In the past, cardiac serine/threonine phosphatases have been studied using phosphorylase a as substrate. Here, type 1 and type 2A phosphatase activities were studied in preparations from failing human hearts using phosphorylated phospholamban and phospholemman as substrates. Phospholamban and phospholemman phosphatase activity was detectable in human cardiac homogenates. Moreover, using a heparin-Sepharose column, the catalytic subunits of type 1 and type 2A phosphatases could be separated from human ventricles. Okadaic acid and cantharidin inhibited phosphatase activities dephosphorylating phospholamban, phospholemman, and phosphorylase a in homogenates in a concentration-dependent manner. However, okadaic acid was more potent. Cantharidin inhibited type 2A and type 1 activities against all substrates studied with IC50 values <15 nM and >290 nM, respectively. Okadaic acid inhibited type 1 and type 2A phosphatase activities as effectively but 10-30 times more potently than cantharidin. This work provides evidence that in the human heart, type 1 and 2A phosphatases are involved in the dephosphorylation of phospholamban and phospholemman and could play a role in the effects of β-adrenergic stimulation in the heart.

Original languageEnglish
Pages (from-to)188-193
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume289
Issue number1
StatePublished - Apr 1999

Fingerprint

Phosphoprotein Phosphatases
Phosphoric Monoester Hydrolases
Cantharidin
Pharmacology
Okadaic Acid
Phosphorylase a
Adrenergic Receptors
Phosphorylation
Adrenergic Agents
Inhibitory Concentration 50
phospholemman
Catalytic Domain
phospholamban

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacological characterization of protein phosphatase activities in preparations from failing human hearts. / Neumann, Joachim; Maas, Renke; Bokník, Peter; Jones, Larry; Zimmermann, Norbert; Scholz, Hasso.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 289, No. 1, 04.1999, p. 188-193.

Research output: Contribution to journalArticle

Neumann, Joachim ; Maas, Renke ; Bokník, Peter ; Jones, Larry ; Zimmermann, Norbert ; Scholz, Hasso. / Pharmacological characterization of protein phosphatase activities in preparations from failing human hearts. In: Journal of Pharmacology and Experimental Therapeutics. 1999 ; Vol. 289, No. 1. pp. 188-193.
@article{f93c6a93443c4f7084fd1d3fad27184e,
title = "Pharmacological characterization of protein phosphatase activities in preparations from failing human hearts",
abstract = "β-Adrenoceptor stimulation acts in the heart in part by increasing the phosphorylation state of phospholamban and phospholemman. There is evidence that the β-adrenoceptor-mediated increase in phospholamban phosphorylation is in part due to inhibition of type 1 phosphatases. The aim of the present study was to elucidate which phosphatases dephosphorylate phospholamban and phospholemman in the human heart. In the past, cardiac serine/threonine phosphatases have been studied using phosphorylase a as substrate. Here, type 1 and type 2A phosphatase activities were studied in preparations from failing human hearts using phosphorylated phospholamban and phospholemman as substrates. Phospholamban and phospholemman phosphatase activity was detectable in human cardiac homogenates. Moreover, using a heparin-Sepharose column, the catalytic subunits of type 1 and type 2A phosphatases could be separated from human ventricles. Okadaic acid and cantharidin inhibited phosphatase activities dephosphorylating phospholamban, phospholemman, and phosphorylase a in homogenates in a concentration-dependent manner. However, okadaic acid was more potent. Cantharidin inhibited type 2A and type 1 activities against all substrates studied with IC50 values <15 nM and >290 nM, respectively. Okadaic acid inhibited type 1 and type 2A phosphatase activities as effectively but 10-30 times more potently than cantharidin. This work provides evidence that in the human heart, type 1 and 2A phosphatases are involved in the dephosphorylation of phospholamban and phospholemman and could play a role in the effects of β-adrenergic stimulation in the heart.",
author = "Joachim Neumann and Renke Maas and Peter Bokn{\'i}k and Larry Jones and Norbert Zimmermann and Hasso Scholz",
year = "1999",
month = "4",
language = "English",
volume = "289",
pages = "188--193",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Pharmacological characterization of protein phosphatase activities in preparations from failing human hearts

AU - Neumann, Joachim

AU - Maas, Renke

AU - Bokník, Peter

AU - Jones, Larry

AU - Zimmermann, Norbert

AU - Scholz, Hasso

PY - 1999/4

Y1 - 1999/4

N2 - β-Adrenoceptor stimulation acts in the heart in part by increasing the phosphorylation state of phospholamban and phospholemman. There is evidence that the β-adrenoceptor-mediated increase in phospholamban phosphorylation is in part due to inhibition of type 1 phosphatases. The aim of the present study was to elucidate which phosphatases dephosphorylate phospholamban and phospholemman in the human heart. In the past, cardiac serine/threonine phosphatases have been studied using phosphorylase a as substrate. Here, type 1 and type 2A phosphatase activities were studied in preparations from failing human hearts using phosphorylated phospholamban and phospholemman as substrates. Phospholamban and phospholemman phosphatase activity was detectable in human cardiac homogenates. Moreover, using a heparin-Sepharose column, the catalytic subunits of type 1 and type 2A phosphatases could be separated from human ventricles. Okadaic acid and cantharidin inhibited phosphatase activities dephosphorylating phospholamban, phospholemman, and phosphorylase a in homogenates in a concentration-dependent manner. However, okadaic acid was more potent. Cantharidin inhibited type 2A and type 1 activities against all substrates studied with IC50 values <15 nM and >290 nM, respectively. Okadaic acid inhibited type 1 and type 2A phosphatase activities as effectively but 10-30 times more potently than cantharidin. This work provides evidence that in the human heart, type 1 and 2A phosphatases are involved in the dephosphorylation of phospholamban and phospholemman and could play a role in the effects of β-adrenergic stimulation in the heart.

AB - β-Adrenoceptor stimulation acts in the heart in part by increasing the phosphorylation state of phospholamban and phospholemman. There is evidence that the β-adrenoceptor-mediated increase in phospholamban phosphorylation is in part due to inhibition of type 1 phosphatases. The aim of the present study was to elucidate which phosphatases dephosphorylate phospholamban and phospholemman in the human heart. In the past, cardiac serine/threonine phosphatases have been studied using phosphorylase a as substrate. Here, type 1 and type 2A phosphatase activities were studied in preparations from failing human hearts using phosphorylated phospholamban and phospholemman as substrates. Phospholamban and phospholemman phosphatase activity was detectable in human cardiac homogenates. Moreover, using a heparin-Sepharose column, the catalytic subunits of type 1 and type 2A phosphatases could be separated from human ventricles. Okadaic acid and cantharidin inhibited phosphatase activities dephosphorylating phospholamban, phospholemman, and phosphorylase a in homogenates in a concentration-dependent manner. However, okadaic acid was more potent. Cantharidin inhibited type 2A and type 1 activities against all substrates studied with IC50 values <15 nM and >290 nM, respectively. Okadaic acid inhibited type 1 and type 2A phosphatase activities as effectively but 10-30 times more potently than cantharidin. This work provides evidence that in the human heart, type 1 and 2A phosphatases are involved in the dephosphorylation of phospholamban and phospholemman and could play a role in the effects of β-adrenergic stimulation in the heart.

UR - http://www.scopus.com/inward/record.url?scp=0032893050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032893050&partnerID=8YFLogxK

M3 - Article

C2 - 10087003

AN - SCOPUS:0032893050

VL - 289

SP - 188

EP - 193

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -